WO2007079202A3 - Treatment for acute lymhoblastic leukemia - Google Patents

Treatment for acute lymhoblastic leukemia Download PDF

Info

Publication number
WO2007079202A3
WO2007079202A3 PCT/US2006/049524 US2006049524W WO2007079202A3 WO 2007079202 A3 WO2007079202 A3 WO 2007079202A3 US 2006049524 W US2006049524 W US 2006049524W WO 2007079202 A3 WO2007079202 A3 WO 2007079202A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
lymhoblastic
acute
treatment
patient
Prior art date
Application number
PCT/US2006/049524
Other languages
French (fr)
Other versions
WO2007079202A2 (en
Inventor
Jeffrey S Miller
Carla Yunis
Original Assignee
3M Innovative Properties Co
Jeffrey S Miller
Carla Yunis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Jeffrey S Miller, Carla Yunis filed Critical 3M Innovative Properties Co
Publication of WO2007079202A2 publication Critical patent/WO2007079202A2/en
Publication of WO2007079202A3 publication Critical patent/WO2007079202A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The present invention provides a method for treating acute lymphoblastic leukemia. Generally, the method includes administering to a patient with ALL an amount of a TLR agonist compound effective to decrease the percentage of leukemic cells in the patient's peripheral blood or bone marrow.
PCT/US2006/049524 2005-12-28 2006-12-28 Treatment for acute lymhoblastic leukemia WO2007079202A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75447405P 2005-12-28 2005-12-28
US60/754,474 2005-12-28

Publications (2)

Publication Number Publication Date
WO2007079202A2 WO2007079202A2 (en) 2007-07-12
WO2007079202A3 true WO2007079202A3 (en) 2007-08-23

Family

ID=38228862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049524 WO2007079202A2 (en) 2005-12-28 2006-12-28 Treatment for acute lymhoblastic leukemia

Country Status (1)

Country Link
WO (1) WO2007079202A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045260A1 (en) 2003-08-12 2005-10-19 3M Innovative Properties Co COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED
AR045529A1 (en) 2003-08-27 2005-11-02 3M Innovative Properties Co IMIDAZOQUINOLINAS REPLACED WITH ARILOXI OR ARILALQUILENOXI GROUPS
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CN1897948A (en) 2003-10-03 2007-01-17 3M创新有限公司 Alkoxy substituted imidazoquinolines
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co Oxime substituted imidazo ring compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
JP4891088B2 (en) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー Substituted imidazo ring systems and methods
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040141950A1 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20040162309A1 (en) * 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8

Also Published As

Publication number Publication date
WO2007079202A2 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
WO2007079169A3 (en) Treatment for acute myeloid leukemia
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
EP2100614B8 (en) Antibody against PDGFR-alpha for use in the treatment of tumours
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
WO2004080430A3 (en) Methods of improving skin quality
UA90467C2 (en) Use of peptide compounds for treating pain in painful diabetic neuropathy
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006078463A3 (en) Method for treating cardiovascular disease
WO2003087831A3 (en) Proteins involved in breast cancer
EP1742643A4 (en) Modulation of glucose-6-phosphatase translocase expression
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2005060960A3 (en) Use of histamine to treat bone disease
SE0102147D0 (en) New methods
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
WO2008008468A3 (en) Compositions and methods for fat reduction

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848302

Country of ref document: EP

Kind code of ref document: A2